Le Lézard
Classified in: Health
Subjects: NPT, AVO

Nurse Practitioners Urge States to Modernize Laws to Combat Opioid Epidemic


WASHINGTON, Nov. 14, 2019 /PRNewswire/ -- During National Nurse Practitioner Week, the American Association of Nurse Practitioners (AANP) is renewing its call for all state legislatures to remove regulatory roadblocks that limit nurse practitioners (NPs) from prescribing Medication-Assisted Treatments (MATs) to their patients struggling with opioid use disorder. Bipartisan federal legislation, the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, enables NPs and other qualified providers to obtain a waiver to prescribe MATs following completion of a 24-hour course. However, some states still limit, and one state, Tennessee, prevents NPs from prescribing patients these important treatments in the fight against opioids. For example, some states require NPs who have received a waiver to prescribe MATs to contract with a physician, who must also be waivered, in order to treat patients with opioid-use disorder.

American Association of Nurse Practitioners (PRNewsfoto/American Association of Nurse P)

As of 2019, more than 11,000 NPs hold a waiver to prescribe the critically important medications. Despite this progress, access to care has been limited by complex and outdated state laws. As a result, nearly 90 percent of all clinicians that hold waivers are clustered in urban areas. As of today, less than half the counties nationwide had a single provider licensed to prescribe buprenorphine, which helps explain why only 20 percent of people with opioid use disorder receive any treatment.

"This is where NPs will have the biggest impact," said Sophia L. Thomas DNP, APRN, FNP-BC, PPCNP-BC, FNAP, FAANP, President of AANP. "NPs are more likely to practice in rural and underserved regions. This broader coverage is absolutely essential. Furthermore, NPs practicing in states with full practice authority (FPA) ? where they practice autonomously ? are more likely to be waivered or pursue a buprenorphine waiver than those who practice in states with restricted practice laws."

"The bottom line is that empowering NPs to treat opioid use disorder increases access for patients who have historically fallen through the cracks," said David Hebert, CEO of AANP. "This is the breakthrough our nation needs to combat the opioid epidemic, and we will continue to work with governors and state legislators to ensure needless barriers are removed and patients suffering from opioid use disorder (OUD) get the care they need in a timely manner."

The American Association of Nurse Practitioners?(AANP) is the largest professional membership organization for nurse practitioners (NPs) of all specialties. It represents the interests of the more than 270,000 licensed NPs in the U.S. AANP provides legislative leadership at the local, state and national levels, advancing health policy; promoting excellence in practice, education and research; and establishing standards that best serve NPs' patients and other health care consumers. As?The Voice of the Nurse Practitioner®, AANP represents the interests of NPs as providers of high-quality, cost-effective, comprehensive, patient-centered health care. For more information and to locate an NP in your community, visit?WeChooseNPs.org.

SOURCE American Association of Nurse Practitioners


These press releases may also interest you

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...

at 11:25
TimelyCare, higher education's most trusted virtual health and well-being provider, has earned recognition as one of the World's Best Digital Health Companies by Newsweek, and has been awarded five Top Workplaces Awards for culture excellence....

at 11:16
Avanos Medical, Inc. will webcast its conference call discussing financial results and business highlights for the first quarter 2024 on Thursday, May 2 at 9 a.m., ET. The company will issue a news release detailing its results before the market...

at 11:15
Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced the approval to expand the use of vebreltinib (also referred...

at 11:10
Through its 2030 Strategic Plan, NJII plans to double the size of the organization and to exceed $70M revenue as it rolls out various new initiatives focused on accelerating technology translation, spurring innovation and upskilling workers. As...

at 11:09
ScreenPoint Medical, today announced a significant transition in its leadership as Mark Koeniguer, the current CEO, steps down from his position. Mark served as CEO since 2022 and was instrumental in ScreenPoint's commercial growth and success over...



News published on and distributed by: